AZN Jul 2024 84.000 call
| Previous close | 0.1200 |
| Open | 0.1200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 84.00 |
| Expiry date | 2024-07-05 |
| Day's range | 0.1200 - 0.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class? Mizuho Healthcare Equity Strategist Jared Holz joins Morning Brief to give insight into the healthcare sector and what investors should keep in mind moving forward. "I think for me, Novo and Lilly are still going to be the top two. You know, as long as they are dominating in this kind of section of the market, it's really tough to not ride these a little bit longer, as far as other players in the GLP one market that might emerge that are of interest or intrigue to investors," Holz says. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China
ZacksAstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
BenzingaChina Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
On Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations. On Tuesday, the Tagrisso with pemetrexed and platinum-based chemotherapy regime received approval in Japan for the same indication. China's National
